Until recently strategies for controlling Classical Swine Fever Virus (CSFV) involve either prophylactic vaccination or non-vaccination with elimination of infected herds depending on the epidemiological situation of the affected geographical area. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement "stamping out" measures. 
Introduction
Classical swine fever (CSF) is a highly contagious disease of swine. The etiological agent, CSF virus (CSFV), is a small, enveloped virus with a positive, single-stranded RNA genome, classified as a member of the genus Pestivirus within the family Flaviridae (Fauquet et al., 2005) . The 12.5 kb CSFV genome contains a single open reading frame that encodes a 3898-amino-acid polyprotein and ultimately yields 11 to 12 final cleavage products (NH 2 -Npro-C-E rns -E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH) through co-and post-translational processing of the polyprotein by cellular and viral proteases (Rice, 1996) . Structural components of the CSFV virion include the capsid (C) protein and glycoproteins E rns , E1, and E2. E1 and E2 are anchored to the envelope at their carboxyl termini and E rns loosely associates with the viral envelope (Thiel et al., 1991; Weiland et al., 1990; . E1
and E2 are type I transmembrane proteins with an N-terminal ectodomain and a C-terminal hydrophobic anchor (Thiel et al., 1991) . E2 is the most immunogenic of the CSFV glycoproteins (Konig et al., 1995; van Gennip et al., 2000; Weiland et al., 1990) , inducing neutralizing antibodies, which provide protection against lethal CSFV challenge. The two main policies used for CSFV control are prophylactic vaccination or non-vaccination with "stamping out" of exposed animals in the event of an outbreak. Countries considered free of CSF do not recommend the use of currently available live attenuated viruses (LAVs) as tools to control outbreaks of the disease, despite the proven efficacy of these vaccines in eliciting a rapid and solid protection against the virus (van Oirschot, 2003) . The humoral immune response induced by these vaccines does not differ from that elicited by infections caused by wild-type viruses; hence, the use of CSFV LAVs has been hampered by their inability of inducing a response differentiable between infected and vaccinated animals (DIVA capability). Thus, the use of a CSFV LAV with DIVA capabilities could significantly impact policies of disease control. CSFV subunit marker vaccines with DIVA capabilities have been developed using recombinant CSFV E2 envelope protein (Hulst et al., 1993; van Rijn et al., 1996; . The onset of immunity elicited by subunit vaccines Virology 384 (2009) Contents lists available at ScienceDirect Virology j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / y v i r o occurs 2 weeks post-vaccination, limiting their efficacy relative to traditional LAV vaccines when animals are exposed to CSFV shortly after vaccination (Bouma et al., 2000; Uttenthal et al., 2001) . Infectious clone technology has recently enabled antigenic modification of attenuated CSFV strains for use as experimental LAV marker vaccines. Infectious clones of the C-strain have been used to replace the antigenic region of E2 and/or the complete E rns gene with analogous sequences derived from Bovine Viral Diarrhea Virus (BVDV) (van Gennip et al., 2000) . Also, promising experimental results were obtained with chimeric viruses using a BVDV infectious clone where the E2 gene was replaced with analogous sequences derived from CSFV strain Alfort (Reimann et al., 2004) . Preliminary data suggest that all these chimeric vaccine viruses were able to induce protection in pigs and, significantly, chimera-induced anti-CSFV antibody responses could be discriminated from those produced by parental viruses.
In this study, we present the development of a CSFV experimental marker LAV strain, FlagT4v, containing the inserted synthetic epitope, Flag ® (Sigma, St. Louis, MO), that serves as a positive antigenic marker, and the abolition of a highly conserved CSFV-specific epitope recognized by monoclonal antibody WH303 (mAbWH303e), that serves as a negative antigenic marker (Edwards et al., 1991) . Intranasal immunization with FlagT4v induced complete protection against challenge with virulent CSFV Brescia, both at 3 and 28 days postinfection (DPI). Intramuscular administration of FlagT4v to swine elicited complete protection against CSFV Brescia starting 2 DPI. Serological responses against both the Flag and mAbWH303 epitopes in animals immunized with FlagT4v allowed the discrimination of animals immunized with FlagT4v from animals challenged with CSFV Brescia. Furthermore, novel real-time reverse transcriptase polymerase chain reaction (rtRT-PCR) assays accurately distinguished FlagT4v and wild-type CSFV Brescia RNAs.
Results

Rescue of FlagT4v
Infectious RNA was in vitro transcribed from full-length ICs of the FlagT4v (Fig. 1 ) and used to transfect SK6 cells as described earlier (Risatti et al., 2005a) . Viruses were rescued from transfected cells by day 4 post-transfection. Full-length nucleotide sequences of the rescued virus genomes were identical to parental DNA plasmids, confirming that only predicted mutations were reflected in rescued viruses.
In vitro growth characteristics of FlagT4v were evaluated relative to parental BICv in a single-step growth curve. SK6 cell cultures were infected at a multiplicity of infection (MOI) of 0.01 TCID50 per cell. Virus was adsorbed for 1 h (time zero), and samples were collected at 72 h post-infection (PI). Samples were titrated in SK6 cells, the presence of virus detected by immunoperoxidase, and titers calculated as described by Risatti et al. (2005a) . Results (data not shown) showed that FlagT4v had an approximately 10-fold decrease in the final virus progeny yield relative to parental BICv (reaching titers of 5.2 (SD: ±0.45) TCID50/ml and 6.04 (SD: ±0.07), respectively).
Additionally, FlagT4v was tested for the ability to form plaques in SK6 cells, exhibiting a significant reduction in plaque size relative to BICv (Fig. 3) . This small plaque phenotype is expected since both parental viruses, RB-C22v and T4v, showed small plaque phenotypes relative to the parental virus BICv in SK6 cultures (Risatti et al., 2005b; 2006) .
The antigenic profile of FlagT4v was evaluated regarding its reactivity against monoclonal antibodies (mAbs) anti-Flag, WH303, and WH174. FlagT4v strongly reacted with mAbs anti-Flag and WH174, while completely lacking reactivity with mAb WH303. Conversely, BICv reacted with both mAbs WH303 and WH174, but failed to react with mAb anti-Flag (Fig. 1B) .
FlagT4v protects pigs against lethal CSFV challenge
The ability of FlagT4v to induce protection against virulent BICv was assessed in early and late vaccination-exposure experiments. Groups of pigs (n = 4) were intranasally (IN) inoculated with FlagT4v and challenged at 3 or 28 DPI. Mock-vaccinated control pigs receiving BICv only (n = 4) developed anorexia, depression, and fever by 4 days post-challenge (DPC), a marked reduction of circulating leukocytes and platelets by 4 DPC (Fig. 2) , and died or were euthanized in extremis by 8-10 DPC. Notably, FlagT4v induced complete clinical protection within 3 days after immunization. All pigs survived infection and remained clinically normal, without fever or significant changes in their hematological values (Fig. 2) . Pigs challenged at 28 days postFlagT4v-infection were also protected, remaining clinically normal, with no alterations of hematological profiles (Fig. 2) or presence of fever. Viremia and virus shedding of vaccinated and challenged exposed animals were examined at 3, 4, 6, 8, 12, 14 and 21 DPC. Detection was performed using mAb WH303, which reacts specifically with the challenge virus BICv. As expected, in mock-vaccinated control animals, viremia was observed within 4 days after challenge, with virus titers remaining high by 8 DPC, the last time point tested before animals died or were euthanized. Furthermore, the challenge virus was detected in nasal swabs and tonsil scrapings of mock-vaccinated between 4 and 8 DPC. Conversely, animals inoculated with FlagT4v and challenged with BICv at 3 or 28 DPI did not present viremia or virus shedding. BICv was not detected in nasal, tonsil or blood samples during the 21-day observation period. These results indicate that protection induced by FlagT4v was complete, preventing both the presentation of CSF-related clinical signs and the replication of the challenge virus.
Intranasally inoculated, CSFV Brescia replicates primarily in tonsils, and then the infection expands to secondary target lymphoid organs (Risatti et al., 2005a; 2005b; 2006) . Thus, CSFV replication in tonsils seems to be a critical step before generalization of the infection in pigs after IN inoculation. To understand mechanisms mediating early protection we looked into the early events of CSFV replication that take place in the host soon after IN inoculation. The simultaneous presence of both FlagT4v and BICv in the main target organs including palatine tonsil, mandibular and retropharyngeal lymph nodes, and spleen was analyzed at different time points after infection with FlagT4v or BICv. Three groups of animals were IN inoculated with 10 5 TCID50 of either FlagT4v or BICv, or received FlagT4v followed by challenge with BICv at 3 DPI. Two animals from each of the groups inoculated with FlagT4v or BICv were euthanized at 3, 5 and 7 DPI. Pigs in the exposure-challenge group were euthanized at days 1, 3, 5, and 7 after receiving the BICv challenge. Tonsils, mandibular lymph nodes (MLN), retropharyngeal lymph nodes (RPLN), and spleen were removed from all animals immediately at necropsy. The presence of each virus in all collected organs was examined by virus titration in SK6 cells. As expected, in animals inoculated with BICv, virus titers were detected in tonsils at 3 DPI, increasing significantly at 5 and 7 DPI (Table 1 ). In this group of animals, titers of BICv also increased in draining retropharyngeal and mandibular lymph nodes, as well as in spleen, from 3 DPI to 7 DPI (Table 1) . Animals infected with FlagT4v showed virus titers, as detected with mAb anti-Flag, in tonsils by 3 DPI increasing slightly towards 5 and 7 DPI, albeit the magnitude of these titers were 100-fold lower relative to virus titers observed in tonsils derived from animals inoculated with BICv (Table 1) . Furthermore, titers of FlagT4v were also reduced 100-fold in retropharyngeal and mandibular lymph nodes relative to BICv infected animals, and detected only at 3 and 5 DPI ( with mAb WH303, at all tested time points (1, 3, 5, and 7 DPC) ( Table 1) . These results would suggest that after challenge, BICv does not replicate in FlagT4v infected animals (sensitivity of detection N1.8 TCID50/ml).
To further confirm these results, the presence of FlagT4v and BICv in tonsils was assessed by immunofluorescence using mAbs anti-Flag or WH303. Results corroborate previous observations. Tonsils from animals infected with FlagT4v showed a weak but clear fluorescent signal with mAb anti-Flag in samples obtained at 3, 5 and 7 DPI. Moreover, tonsils obtained from BICv-infected animals showed strong reactivity with mAb WH303 at all days tested. Furthermore, FlagT4v was detected in tonsils obtained from animals in the FlagT4v-infected/BICv-challenged group, whereas no signal was observed when using mAb WH303 at any of the tested time points (1, 3, 5 and 7 DPC).
Intramuscular (IM) administration of FlagT4v induces protection 2 days after challenge with virulent CSFV
The early induction of protection after vaccination is of paramount importance during a disease outbreak. Therefore, the ability of FlagT4v on inducing protection earlier than 3 DPC was evaluated in a vaccination/challenge experiment. Five groups of animals (n = 4) were IM inoculated with 10 (Table 2) .
Differential antibody responses in FlagT4v inoculated pigs
The anti-Flag serological response in animals infected with FlagT4v via IN or IM routes was tested at 28 DPI using an in-house ELISA assay. Animals infected by IN (N = 4) and IM (N = 3) routes developed a strong anti-Flag antibody response with average titers of (log 10 ) 2.67 (SD 0.07) or (log 10 ) 2.71 (SD 0.08), respectively. Sera from animals infected with viruses lacking the Flag epitope presented OD readings comparable with those obtained with non-immune sera (Fig. 3B) .
The presence of an anti-mAbWH303e antibody response was analyzed in FlagT4v vaccinated animals (N = 7) also at 28 DPI. An inhouse competitive ELISA test was developed, where the ability of mAbWH303 labeled with HRP to bind to a peptide, representing mAbWH303e, would be out-competed with sera derived from pigs immunized with FlagT4v or with sera derived from pigs infected with viruses harboring an unmodified mAbWH303e. Results showed that the sera from FlagT4v-infected animals (N = 7) were as unable to compete with mAbWH303 as a group of sera obtained from mockinfected pigs (N = 4) was, indicating a lack of anti-mAb303e antibodies (Fig. 3A) . Conversely, a pool of sera (N = 4) obtained from animals infected with viruses harboring an unaltered mAbWH303e efficiently out-competed the HRP-labeled mAbWH303, precluding binding with mAbWH303e (Fig. 3A) . Interestingly, sera obtained from seven animals vaccinated with FlagT4v 21 days after challenge with BICv showed a slightly increased ability to compete with mAbWH303. It is important to notice that with the exception of the mock-infected sera, all sera used here showed anti-CSFV activity as determined by Checkit CSFV-sero (IDEXX, The Netherlands) and virus seroneutralization assays (data not shown). Taken together, the serological results showed that FlagT4v was able to induce a specific antibody response by 28 DPI that was distinguishable from the antibody response induced by BICv-derived viruses lacking a Flag epitope but harboring an intact mAbWH303e.
Genetic based distinction between FlagT4v and BICv
We used an rtRT-PCR TaqMan ® based approach to distinguish between isolated FlagT4v and BICv. A duplex one-step rtRT-PCR was designed using TaqMan ® probes, labeled with TET or 6FAM fluorochromes, targeting the genomic regions encoding for the Flag epitope in FlagT4v and the genomic region encoding for mAbWH303e. Combination of primers, probes, with RNA from either of the viruses in independent reactions allowed distinction between FlagT4v (6FAM channel) and BICv (TET channel). Signals were observed only when the correct target RNA was included in the reaction probing the specificity of the assay (Fig. 4) .
Discussion
We present here an approach for rationally developing of an experimental live attenuated marker CSFV vaccine strain. The candidate vaccine virus, FlagT4v, harbors functional positive and negative antigenic markers that confer potential DIVA capabilities. The virus elicits solid protection against challenge with highly virulent BICv (Brescia strain) by 3 DPI when administered intranasally, or as early as 2 DPI when administered intramuscularly in swine. Response to FlagT4v can be distinguished from a wild-type CSF virus (i.e., Brescia strain) by means of serology.
The majority of CSF control programs in enzootic areas are based on prophylactic vaccination of domestic pigs. Vaccination with live attenuated vaccine (LAV) strains induce protective immunity in pigs within a few days after vaccination, even before neutralizing antibodies can be detected, providing lifelong immunity against disease (Biront and Leunen, 1988; Terpstra, 1991) . However, current LAVs lack DIVA capabilities that would allow differentiation between infected and vaccinated animals, limiting their use as an emergency control strategy in the event of an outbreak in CSFV-free regions. CSFV subunit marker vaccines with DIVA capabilities have been developed using recombinant E2 envelope protein (Hulst et al., 1993; van Rijn et al., 1996; . These vaccines are commercially available and have proven to induce solid and long lasting immunity approximately 2 weeks after vaccination. This delayed onset of immunity against CSFV makes them undesirable for use in emergency vaccination programs (Bouma et al., 2000; Uttenthal et al., 2001) . Thus, there is an increased need for developing LAVs against CSFV with DIVA capabilities Dong and Chen, 2007) . These vaccines, while inducing a rapid and effective immunity, should harbor antigenic markers for serological distinction of infected from vaccinated animals. In addition, a rapid molecular diagnostic test, such as real-time RT-PCR, should accurately distinguish vaccinated and wild-type infected field isolates.
FlagT4v has been developed using this approach. Attenuation of FlagT4v was achieved by manipulating two independent novel genetic determinants of viral virulence (Risatti et al., 2005b; 2006) . So far, experimental CSFV LAV candidates have been designed based on the use of the genetic backgrounds of known LAV CSFV vaccine strains (van Gennip et al., 2000; Wehrle et al., 2007) or other Pestiviruses (i.e., BVDV) that replicate in pigs without causing disease (Reimann et al., 2004) . The genetic determinants of attenuation in these two approaches remain to be elucidated.
Early protection is a critical aspect to be addressed in development of novel LAVs for use during a CSFV outbreak in areas free of disease. Most CSFV experimental vaccines developed to date have been tested for their potency against challenge between 2 to 4 weeks postvaccination, lacking data about how efficacious these vaccines are if tested in shorter vaccination-to-exposure trials that eventually will make them suitable for emergency vaccination. Notably, FlagT4v is able to induce a solid protection status in swine from day 3 postinoculation when administered intranasally, or from day 2 postinoculation when delivered intramuscularly. Replication of challenge virus in FlagT4v-inoculated animals appears to be severely restricted or completely undetectable (Tables 1). Immune mechanisms mediating this early protection are still unknown. It is possible that an effect compatible with interference mediated by direct competition between FlagT4v and BICv might occur, where a combination of mechanisms such as direct occupancy of target cells by FlagT4v precluding entry of BICv or release of soluble inhibitory factors from FlagT4-infected cells are involved.
FlagT4v-infected animals develop a serological antibody response that, analyzed at 28 DPI, allows a differentiation relative to the serologic profile observed in mock-vaccinated animals or in animals infected with attenuated CSF viruses lacking the antigenic markers. Therefore, anti-Flag antibodies were readily detected in all FlagT4v-infected animals showing titers reaching above (log 10 ) 2.00, while anti-CSFV sera (positive by commercial ELISA tests) lacked anti-Flag reactivity comparable to sera obtained from mock-infected animals. Similarly, no reactivity was detected in sera obtained from FlagT4v (also positive by commercial ELISA tests) or mock-infected animals against the mAbWH303e; reactivity against this epitope was detected in sera obtained from animals infected with viruses harboring an intact mAbWH303e. Besides the distinctive serological profile elicited by FlagT4v, isolated virus can be differentiated from BICv by genetic means (Fig. 4) . In summary, we present here the development of a rationally designed CSFV double antigenically marked experimental vaccine with DIVA capabilities. The candidate vaccine virus is able to induce protection against challenge with a highly virulent strain of CSFV, and elicits an antibody response that can be differentiated from the response induced by the wild-type virus.
Materials and methods
Viruses and cells
Swine kidney cells (SK6) (Terpstra et al., 1990) , free of BVDV, were cultured in Dulbecco's minimal essential media (DMEM) (Gibco, Grand Island, NY) with 10% fetal calf serum (FCS) (Atlas Biologicals, Fort Collins, CO). CSFV derived from full-length cDNA copies, including CSFV Brescia strain (BICv) (Risatti et al., 2005a) , RB-C22v (Risatti et al., 2005b) , T4v (Risatti et al., 2006) , and FlagT4v (this study) were propagated in SK6 cells. Titration of CSFV from clinical samples was performed using SK6 cells in 96-well plates (Costar, Cambridge, MA). Viral infectivity was detected, after 4 days in culture, by an immunoperoxidase assay using the CSFV monoclonal antibody (mAb) WH174 (kindly provided by Georgina Ibata, Veterinary Laboratory Agency, UK) or mAb WH303, and the Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Titers were calculated using the method of Reed and Muench (1938) and expressed as TCID50/ml. As performed, test sensitivity was N1.8 TCID50/ml. Plaque assays were performed using SK6 cells in 6-well plates (Costar). SK6 monolayers were infected, overlaid with 0.5% agarose and incubated at 37°C for 3 days. Plates were fixed with 50% (vol/vol) ethanol-acetone and stained by immunohistochemistry with mAbs WH174, WH303 (Edwards et al., 1991) or anti-Flag (Sigma, St. Louis, MO).
Construction of CSFV FlagT4v
A full-length cDNA copy of RB-C22v (Risatti et al., 2005b) was NotINheI digested and the excised 46 nucleotide fragment replaced with an oligonucleotide, forward sequence 5′ GGCCGCAGATTACAAGGATGAC-GACGATAAGGGGGCAC AAGGCCGG 3′ and reverse complementary sequence 5′ CTAGCCGGCCTTGTGCCC CCTTATCGTCGTCATCCTTGTAATC-TGC 3′, encoding for the Flag epitope DYKDDDDK (bold case) (Fig 1A) . One hundred picomoles of the forward and reverse oligonucleotides were annealed in buffer containing 10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA. Oligonucleotides were heated at 95°C for 5 min then cooled at room temperature for 30 min. Annealed oligonucleotides were directionally cloned into NotI-NheI digested pRB-C22 using T4 DNA ligase (New England Biolabs, Beverley, MA). The introduction of mutations in amino acids at positions 829 to 834 of the CSFV polyprotein resulting in a shift of the Brescia amino acid sequence (TAVSPT) to the corresponding residues in bovine viral diarrhea virus (BVDV) strain NADL (TSFNMD) were performed on the pFlag-T4 exactly as described by Risatti et al. (2006) for the development of the T4 virus (Fig. 1B) .
In vitro rescue of CSFV Brescia and FlagT4v
Full-length genomic clones were linearized with SrfI and in vitro transcribed using the T7 Megascript system (Ambion, Austin, TX). RNA was precipitated with LiCl and transfected into SK6 cells by electroporation at 500 V, 720 ohm, 100 W, with a BTX 630 electroporator (BTX, San Diego, CA). Cells were seeded in 12-well plates and incubated for 4 days at 37°C and 5% CO 2 . Virus was detected by immunoperoxidase staining as described above, and stocks of rescued viruses were stored at −70°C.
DNA sequencing and analysis
Full-length clones and in vitro rescued viruses were completely sequenced with CSFV-specific primers by the dideoxynucleotide chain-termination method (Sanger et al., 1977) . Sequencing reactions were prepared with the Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). Reaction products were sequenced on a PRISM 3730xl automated DNA sequencer (Applied Biosystems). Sequence data were assembled with the Phrap software program (http://www.phrap.org), with confirmatory assemblies performed using CAP3 (Huang and Madan, 1999) . The final DNA consensus sequence represented an average five-fold redundancy at each base position. Sequence comparisons were conducted using BioEdit software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html).
Animal studies
First, 12 pigs were randomly allocated into 3 groups of 4 animals each. Pigs in groups 1 and 2 were intranasally (IN) inoculated with 10 5 TCID50 FlagT4v, and pigs in group 3 were mock-infected. At 3 DPI (group 1) or 28 DPI (group 2), animals were IN challenged with 10 5 TCID50 BICv along with animals in group 3. Clinical signs and body temperature were recorded daily throughout the experiment as previously described (Risatti et al., 2005b) . Blood, serum, nasal swabs and tonsil scrapings were collected at times post-challenge, with blood obtained from the anterior vena cava in EDTA-containing tubes (Vacutainer) for total and differential white blood cell counts. Total and differential white blood cell and platelet counts were obtained using a Beckman Coulter ACT (Beckman Fullerton, Coulter, CA). Tissue samples were collected from animals at death or during postmortem examination and processed as described before (Risatti et al., 2005b) .
To determine the earliest onset of FlagT4v protection swine were allotted into 6 groups of 4 animals each. Five groups were intramuscularly (IM) inoculated with 10 5 TCID50 of FlagT4v, and one additional group was mock inoculated. All groups were then challenged intranasally with 10 5 TCID50 of virulent BICv at day 0, 1, 2, 3, or 28 post-FlagT4v inoculation. Clinical evaluation and sampling of animals was performed as described as Risatti et al., (2005b) . The presence of both FlagT4v and BICv was determined in target organs including palatine tonsil, mandibular (MLN) and retropharyngeal (RPLN) lymph nodes, and spleen at different time points after infection. Three groups of animals were IN inoculated with 10 5 TCID50
of either FlagT4v (group 1, n = 6) or BICv (group 2, n = 6), or received FlagT4v followed by challenge with BICv at 3 DPI (group 3, n = 8). Two animals from groups 1 and 2 were euthanized at 3, 5 and 7 DPI. Pigs in group 3 were euthanized at days 1, 3, 5, and 7 after receiving the BICv challenge. Tissues were removed from all animals and stored at −70°C. Amount of virus in tissues was determined by virus titration in SK6 cells as described above.
Detection of FlagT4v and BICv by immunofluorescence
To assess the presence of FlagT4v and BICv in tonsils of infected/ challenged animals, palatine tonsil samples were collected postmortem in triplicate. Tissues were mounted on polystyrene blocks using Optimal Cutting Temperature (OCT) compound (TissueTek Sakura, Torrance, CA), promptly frozen in liquid nitrogen, and stored at −70°C. Sections of 4 μm in thickness were obtained from each of the triplicate cryopreserved tissue samples and fixed with acetone for 10 min at − 20°C. After fixation, tissue sections were incubated at room temperature (RT) for 90 min in blocking buffer containing 2% (w/v) bovine serum albumin (Sigma) and 20% (v/v) normal bovine serum (Gibco-Invitrogen, Carlsbad, CA) in PBS. Primary mAbs, anti-Flag M2 (Sigma), and WH303 were diluted in blocking buffer and incubated with blocked tissue sections overnight at 4°C in a humid chamber. After washing five times with PBS at RT, tissue sections were incubated for 90 min at 37°C with the appropriate secondary antibodies, goat anti-mouse isotype-specific IgG labeled with either AlexaFluor 488 or AlexaFluor 594 (Molecular Probes-Invitrogen, Carlsbad, CA) diluted in blocking buffer. After incubation, tissue sections were washed 5 times with PBS at RT, counterstained with TOPRO-iodide 642/661 (Molecular Probes) for 5 min at RT, washed 5 times with PBS at RT, mounted, and examined in a Leica Scanning Confocal Microscope (Leica Microsystems, Bannockburn, IL). Data were collected utilizing an appropriate control lacking incubation with primary antibodies in order to determine channel crossover settings, as well as using these antibodies in uninfected tissues to give the negative background level. The captured images were adjusted for contrast and brightness using Adobe Photoshop software (Adobe, San José, CA).
Detection of anti-Flag antibodies
Serological antibody responses against the Flag epitope were determined using an ELISA assay. ELISA plates (Immulon 2HB, Thermo Scientific, West Palm Beach, FL) were coated with Amino-Terminal 3xFlagBAC protein (Sigma) at a concentration of 1 μg/ml diluted in carbonate/bicarbonate buffer 0.05 M, pH 8.6 (Sigma) and incubated overnight at 4°C. Plates were blocked with blocking buffer [PBS containing 5% (w/v) non-fat dry milk and 0.1% Tween-20 (v/v), (Sigma)] for 1 h at 37°C. Serum dilutions, performed in blocking buffer, were incubated on the plates for 1 h at 37°C. After washing 5 times with washing buffer (PBS containing 0.1% Tween-20) plates were incubated with affinity purified goat anti-swine IgG antibody labeled with horseradish peroxidase (HRP) (KPL, Gaithersburg, MD) diluted 1/1000 in blocking buffer for 1 h at 37°C. After washing 5 times with washing buffer, plates were incubated with ABTS Peroxidase Substrate System (KPL) and blocked with Peroxidase Stop Solution (KPL). Readings were done at a wavelength of 405 nm in an ELISA plate reader (Spectra). Titers were expressed as the log 10 of the inverse of the highest serum dilution that at least duplicate the OD readings of a pool of naïve sera.
Detection of anti-mAbWH303e antibodies
Serological antibody responses against mAbWH303e were detected using a competitive ELISA. ELISA plates (Immulon 2HB) were coated with a synthetic peptide representing the mAbWH303e (CTAVSPTTLRTEVVK) coupled to KLH (Celtek BioScience, Nashville, TN) at a concentration of 20 μg/ml diluted in carbonate/bicarbonate buffer (Sigma) and incubated overnight at 4°C. Plates were then blocked with blocking buffer (see above) for 1 h at 37°C. Serum dilutions, performed in blocking buffer, were added to the plates along with HRP labeled mAbWH303 (Covance, USA) followed by an incubation step at room temperature for 90 min with shaking. After washing 5 times with washing buffer, plates were incubated with ABTS Peroxidase Substrate System (KPL) and blocked with Peroxidase Stop Solution (KPL). Readings were done at a wavelength of 405 nm in an ELISA plate reader.
Detection of BICv and FlagT4v by rtRT-PCR
A TaqMan
® based duplex-rtRT-PCR assay was developed and used to distinguish between BICv and FlagT4v. Primers and probes were designed using Primer Express 3.0 software (Applied Biosystems, Foster City, CA). A set of primers with a TET-labeled probe were designed to target nucleotide sequence encoding for mAbWH303e within CSFV E2 glycoprotein. Primers BICv-DIVA1-F (5′AGGGTGGACGGGTGTTATAGA GT3′) and BICv-DIVA1-R (5′TGAAGGTCTTTACCACTTCTGTTCTC3′) were designed to target nucleotide sequences within BICv E2 glycoprotein gene with the probe BICv-DIVA1-Pr (5′TET-CACGGCAGTGA-GCCCGACAACTC3′TAMRA) targeting nucleotide sequence encoding for the mAbWH303e. A second set of primers with a 6FAM-labeled probe were designed to target the nucleotide sequence encoding for Flag epitope inserted at the carboxyl terminal end of CSFV E1 glycoprotein. Primer Flag-DIVA-F (5′GATTACAAGGATGACGACGATAAGG3′) targets a region within E1 genes and Flag-DIVA-R (5′TTGTTGATATAGCG-TACCTGTGATCTT3′) targets a region within E2 gene, while probe Flag-DIVA-Pr (5′6FAM-CACAAGGCCGGCTAGCCTGCA3′TAMRA) targets the Flag epitope. Viral RNA was obtained from BICv and FlagT4v using an RNeasy kit (Qiagen, Valencia, CA). A one step rtRT-PCR was performed using a TaqMan ® EZ RT-PCR Core Reagent kit (Applied Biosystems). A 25 μl reaction was set combining, 500 nM of each of the BICv DIVA primer set, 900 nM of each of the Flag-DIVA primer set, 75 nM of the BICv-DIVA1-Pr, 250 nM of the Flag-DIVA-Pr, 10 mM dNTPs, 2.5 mM Mn (OAc), 5 μl of 5× TaqMan buffer, and 2.5 μl of template RNA (50 ng/ μl). Cycling parameters were 60°C for 10 min, followed by 45 cycles of denaturation at 95°C for 2 s and annealing-extension at 60°C for 30 s.
Reactions were performed in a Smart Cycler instrument (Cepheid, Sunnyville, CA). Fluorescent measurements were recorded during the elongation step. Single rtRT-PCR assays were also performed with each set of primers and probes against RNA from both FlagT4v and BICv to assess assay specificity.
